Search

Your search keyword '"Michihiro Ogasawara"' showing total 3 results
Start Over Author "Michihiro Ogasawara" Publication Year Range Last 3 years
3 results on '"Michihiro Ogasawara"'

1. Risk factors associated with relapse after methotrexate dose reduction in patients with rheumatoid arthritis receiving golimumab and methotrexate combination therapy

Author

Noboru Kitamura, Hitomi Kobayashi, Yosuke Nagasawa, Kaita Sugiyama, Hiroshi Tsuzuki, Yutaka Tanikawa, Natsumi Ikumi, Yuito Okada, Yasuo Takahashi, Satoshi Asai, Naoto Tamura, Michihiro Ogasawara, Toshio Kawamoto, Ryohei Kuwatsuru, Hiromichi Tamaki, Genki Kidoguchi, Mutsuto Tateishi, Makiko Kimura, Yuichi Mochida, Kengo Harigane, Takayuki Shimazaki, Takao Koike, Kazuhide Tanimura, Hiroshi Kataoka, Koichi Amano, Hidekata Yasuoka, and Masami Takei

Subjects
Rheumatology
Published
2023

2. Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren’s syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren’s Syndrome Endocrinopathy) and ROSE II trials

Author

Hiroto Tsuboi, Hirofumi Toko, Fumika Honda, Saori Abe, Hiroyuki Takahashi, Mizuki Yagishita, Shinya Hagiwara, Ayako Ohyama, Yuya Kondo, Kazuhisa Nakano, Yoshiya Tanaka, Toshimasa Shimizu, Hideki Nakamura, Atsushi Kawakami, Yuichiro Fujieda, Tatsuya Atsumi, Yasunori Suzuki, Mitsuhiro Kawano, Naoshi Nishina, Yuko Kaneko, Tsutomu Takeuchi, Hitomi Kobayashi, Masami Takei, Michihiro Ogasawara, Naoto Tamura, Yoshinari Takasaki, Kazuhiro Yokota, Yuji Akiyama, Toshihide Mimura, Kosaku Murakami, Tsuneyo Mimori, Shiro Ohshima, Naoto Azuma, Hajime Sano, Susumu Nishiyama, Isao Matsumoto, and Takayuki Sumida

Subjects
Rheumatology
Abstract

Objective To clarify the efficacy and safety of intravenous abatacept for glandular and extraglandular involvements in Sjögren’s syndrome (SS) associated with rheumatoid arthritis (RA). Materials and methods We performed an open-label, prospective, 1-year, observational multicenter study (ROSE and ROSE II trials). The primary endpoint was the remission rate as measured by SDAI at 52 weeks. The secondary endpoints included the changes in the Saxon’s test, Schirmer’s test, ESSDAI and ESSPRI. Adverse events and adherence rates were also analyzed. Results 68 patients (36 in ROSE and 32 in ROSE II, all women) were enrolled. SDAI decreased significantly from 23.6 ± 13.2 at baseline to 9.9 ± 9.5 at 52 weeks. Patients with SDAI remission increased from 0 (0 weeks) to 19 patients (27.9%) at 52 weeks. Saliva volume increased significantly at 24 weeks. Tear volume increased significantly at 52 weeks. Both ESSDAI and ESSPRI were significantly decreased at 12 weeks, and these responses were maintained up to 52 weeks. The rate of adherence to abatacept over the 52-week period was 83.8%. Twenty-two adverse events occurred in 15 patients. Conclusion Abatacept ameliorated both glandular and extraglandular involvements, as well as the systemic disease activities and patient-reported outcomes based on composite measures, in SS associated with RA.

Published
2022

3. The provisional OMERACT ultrasonography score for giant cell arteritis

Author

Christian Dejaco, Cristina Ponte, Sara Monti, Davide Rozza, Carlo Alberto Scirè, Lene Terslev, George A W Bruyn, Dennis Boumans, Wolfgang Hartung, Alojzija Hočevar, Marcin Milchert, Uffe Møller Døhn, Chetan B Mukhtyar, Markus Aschwanden, Philipp Bosch, Dario Camellino, Stavros Chrysidis, Giovanni Ciancio, Maria Antonietta D’Agostino, Thomas Daikeler, Bhaskar Dasgupta, Eugenio De Miguel, Andreas P Diamantopoulos, Christina Duftner, Ana Agueda, Ulrich Fredberg, Petra Hanova, Ib Tønder Hansen, Ellen-Margrethe Hauge, Annamaria Iagnocco, Nevsun Inanc, Aaron Juche, Rositsa Karalilova, Toshio Kawamoto, Kresten Krarup Keller, Helen Isobel Keen, Tanaz A Kermani, Minna J. Kohler, Matthew Koster, Raashid Ahmed Luqmani, Pierluigi Macchioni, Sarah Louise Mackie, Esperanza Naredo, Berit Dalsgaard Nielsen, Michihiro Ogasawara, Carlos Pineda, Valentin Sebastian Schäfer, Luca Seitz, Alessandro Tomelleri, Karina D Torralba, Kornelis S M van der Geest, Kenneth J Warrington, Wolfgang A Schmidt, Dejaco, C, Ponte, C, Monti, S, Rozza, D, Scire, C, Terslev, L, Bruyn, G, Boumans, D, Hartung, W, Hocevar, A, Milchert, M, Dohn, U, Mukhtyar, C, Aschwanden, M, Bosch, P, Camellino, D, Chrysidis, S, Ciancio, G, D'Agostino, M, Daikeler, T, Dasgupta, B, De Miguel, E, Diamantopoulos, A, Duftner, C, Agueda, A, Fredberg, U, Hanova, P, Hansen, I, Hauge, E, Iagnocco, A, Inanc, N, Juche, A, Karalilova, R, Kawamoto, T, Keller, K, Keen, H, Kermani, T, Kohler, M, Koster, M, Luqmani, R, Macchioni, P, Mackie, S, Naredo, E, Nielsen, B, Ogasawara, M, Pineda, C, Schafer, V, Seitz, L, Tomelleri, A, Torralba, K, Van Der Geest, K, Warrington, K, and Schmidt, W

Subjects
giant cell arteriti, Settore MED/16 - REUMATOLOGIA, giant cell arteritis, outcome assessment, health care, systemic vasculitis, ultrasonography, Immunology, health care, General Biochemistry, Genetics and Molecular Biology, Rheumatology, Immunology and Allergy, 610 Medizin und Gesundheit, systemic vasculiti, outcome assessment
Abstract

ObjectivesTo develop an Outcome Measures in Rheumatology (OMERACT) ultrasonography score for monitoring disease activity in giant cell arteritis (GCA) and evaluate its metric properties.MethodsThe OMERACT Instrument Selection Algorithm was followed. Forty-nine members of the OMERACT ultrasonography large vessel vasculitis working group were invited to seven Delphi rounds. An online reliability exercise was conducted using images of bilateral common temporal arteries, parietal and frontal branches as well as axillary arteries from 16 patients with GCA and 7 controls. Sensitivity to change and convergent construct validity were tested using data from a prospective cohort of patients with new GCA in which ultrasound-based intima–media thickness (IMT) measurements were conducted at weeks 1, 3, 6, 12 and 24.ResultsAgreement was obtained (92.7%) for the OMERACT GCA Ultrasonography Score (OGUS), calculated as follows: sum of IMT measured in every segment divided by the rounded cut-off values of IMTs in each segment. The resulting value is then divided by the number of segments available. Thirty-five members conducted the reliability exercise, the interrater intraclass correlation coefficient (ICC) for the OGUS was 0.72–0.84 and the median intrareader ICC was 0.91. The prospective cohort consisted of 52 patients. Sensitivity to change between baseline and each follow-up visit up to week 24 yielded standardised mean differences from −1.19 to −2.16, corresponding to large and very large magnitudes of change, respectively. OGUS correlated moderately with erythrocyte sedimentation rate, C reactive protein and Birmingham Vasculitis Activity Score (corrcoeff0.37–0.48).ConclusionWe developed a provisional OGUS for potential use in clinical trials.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results